2.01
+0.04(+2.03%)
Currency In USD
| Previous Close | 1.97 |
| Open | 1.97 |
| Day High | 2.04 |
| Day Low | 1.96 |
| 52-Week High | 7.85 |
| 52-Week Low | 1.29 |
| Volume | 388,460 |
| Average Volume | 1.72M |
| Market Cap | 220.53M |
| PE | -1.72 |
| EPS | -1.17 |
| Moving Average 50 Days | 1.95 |
| Moving Average 200 Days | 4.5 |
| Change | 0.04 |
If you invested $1000 in Annexon, Inc. (ANNX) since IPO date, it would be worth $110.92 as of May 22, 2025 at a share price of $1.97. Whereas If you bought $1000 worth of Annexon, Inc. (ANNX) shares 3 years ago, it would be worth $600.61 as of May 22, 2025 at a share price of $1.97.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Annexon Showcases Tanruprubart Data Demonstrating Improved Clinical Outcomes in Guillain-Barré Syndrome (GBS) at 2025 Peripheral Nerve Society (PNS) Annual Meeting
GlobeNewswire Inc.
May 19, 2025 8:05 PM GMT
First Oral Presentation of the Tanruprubart Real-World Evidence (RWE) Study by International Guillain-Barré Syndrome Outcomes Study (IGOS) Researchers Highlights Benefits over Current Standard of Care in Matched Patient Populations Poster Presentatio
Annexon Announces Presentations on the Clinical Advancement of Tanruprubart as the First Potential Targeted Therapy for Guillain-Barré Syndrome (GBS) at the 2025 PNS Meeting
GlobeNewswire Inc.
May 09, 2025 9:00 PM GMT
First Oral Presentation by the International Guillain-Barré Syndrome Outcomes Study (IGOS) of the Real-World Evidence (RWE) Results Showing Improved Outcomes with Tanruprubart (formerly ANX005) Compared to Current Standards of Care in Matched Patient
Annexon to Present on the Neuroprotective Effects of ANX007 at the 2025 ARVO Annual Meeting and the Retina World Congress
GlobeNewswire Inc.
May 07, 2025 12:00 PM GMT
Phase 2 ARCHER Data Support Therapeutic Potential for ANX007 to Preserve Vision in Patients who have Dry Age-related Macular Degeneration (AMD) with Geographic Atrophy (GA) Phase 3 ARCHER II Trial Enrolling Globally BRISBANE, Calif., May 07, 2025 (